Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2012-08

AUTHORS

A. W. Tolcher, K. N. Chi, N. D. Shore, R. Pili, A. Molina, M. Acharya, T. Kheoh, J. J. Jiao, M. Gonzalez, A. Trinh, C. Pankras, N. Tran

ABSTRACT

PURPOSE: Abiraterone is the active metabolite of the pro-drug abiraterone acetate (AA) and a selective inhibitor of CYP17, a key enzyme in testosterone synthesis, and improves overall survival in postdocetaxel metastatic castration-resistant prostate cancer (mCRPC). This open-label, single-arm phase 1b study was conducted to assess the effect of AA and abiraterone on the QT interval. METHODS: The study was conducted in 33 patients with mCRPC. Patients received AA 1,000 mg orally once daily + prednisone 5 mg orally twice daily. Electrocardiograms (ECGs) were collected in triplicate using 12-lead Holter monitoring. Baseline ECGs were obtained on Cycle 1 Day-1. Serial ECG recordings and time-matched pharmacokinetic (PK) blood samples were collected over 24 h on Cycle 1 Day 1 and Cycle 2 Day 1. Serial PK blood samples were also collected over 24 h on Cycle 1 Day 8. RESULTS: After AA administration, the upper bound of the 2-sided 90 % confidence interval (CI) for the mean baseline-adjusted QTcF change was <10 ms; no patients discontinued due to QTc prolongation or adverse events. No apparent relationship between change in QTcF and abiraterone plasma concentrations was observed [estimated slope (90 % CI): 0.0031 (-0.0040, 0.0102)]. CONCLUSIONS: There is no significant effect of AA plus prednisone on the QT/QTc interval in patients with mCRPC. More... »

PAGES

305-313

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00280-012-1916-9

DOI

http://dx.doi.org/10.1007/s00280-012-1916-9

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1053642864

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/22752297


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Abiraterone Acetate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Androgens", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Androstadienes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Electrocardiography", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Heart Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Long QT Syndrome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms, Hormone-Dependent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Orchiectomy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prednisone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prostatic Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Steroid 17-alpha-Hydroxylase", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "South Texas Accelerated Research Therapeutics", 
          "id": "https://www.grid.ac/institutes/grid.477989.c", 
          "name": [
            "South Texas Accelerated Research Therapeutics (START), Center for Cancer Care, 4383 Medical Drive, 78229, San Antonio, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tolcher", 
        "givenName": "A. W.", 
        "id": "sg:person.013317163017.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013317163017.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "British Columbia Cancer Agency, Vancouver, BC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chi", 
        "givenName": "K. N.", 
        "id": "sg:person.01142252161.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01142252161.65"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Carolina Urologic Research Center", 
          "id": "https://www.grid.ac/institutes/grid.476933.c", 
          "name": [
            "Carolina Urologic Research Center, Myrtle Beach, SC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shore", 
        "givenName": "N. D.", 
        "id": "sg:person.01065235371.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01065235371.09"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roswell Park Cancer Institute", 
          "id": "https://www.grid.ac/institutes/grid.240614.5", 
          "name": [
            "Roswell Park Cancer Institute, Buffalo, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pili", 
        "givenName": "R.", 
        "id": "sg:person.01316567341.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01316567341.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Janssen (United States)", 
          "id": "https://www.grid.ac/institutes/grid.497530.c", 
          "name": [
            "Janssen Research & Development LLC, Raritan, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Molina", 
        "givenName": "A.", 
        "id": "sg:person.012576447577.98", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012576447577.98"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Janssen (United States)", 
          "id": "https://www.grid.ac/institutes/grid.497530.c", 
          "name": [
            "Janssen Research & Development LLC, Raritan, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Acharya", 
        "givenName": "M.", 
        "id": "sg:person.01253457116.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01253457116.57"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Janssen (United States)", 
          "id": "https://www.grid.ac/institutes/grid.497530.c", 
          "name": [
            "Janssen Research & Development LLC, Raritan, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kheoh", 
        "givenName": "T.", 
        "id": "sg:person.01142277551.95", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01142277551.95"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Janssen (United States)", 
          "id": "https://www.grid.ac/institutes/grid.497530.c", 
          "name": [
            "Janssen Research & Development LLC, Raritan, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jiao", 
        "givenName": "J. J.", 
        "id": "sg:person.01023060661.71", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01023060661.71"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Janssen (United States)", 
          "id": "https://www.grid.ac/institutes/grid.497530.c", 
          "name": [
            "Janssen Research & Development LLC, Raritan, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gonzalez", 
        "givenName": "M.", 
        "id": "sg:person.01071174061.78", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01071174061.78"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Janssen (United States)", 
          "id": "https://www.grid.ac/institutes/grid.497530.c", 
          "name": [
            "Janssen Research & Development LLC, Raritan, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Trinh", 
        "givenName": "A.", 
        "id": "sg:person.01137307261.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01137307261.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "British Columbia Cancer Agency, Vancouver, BC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pankras", 
        "givenName": "C.", 
        "id": "sg:person.01205422461.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01205422461.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Janssen (United States)", 
          "id": "https://www.grid.ac/institutes/grid.497530.c", 
          "name": [
            "Janssen Research & Development LLC, Raritan, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tran", 
        "givenName": "N.", 
        "id": "sg:person.01253535661.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01253535661.37"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1200/jco.2007.15.9749", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000521921"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdq369", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007763175"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdq369", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007763175"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1014618", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018044872"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2009.25.9259", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026303880"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1046/j.1365-2125.2002.01627.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027770955"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.coph.2008.06.004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030776578"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2007.12.4487", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031178629"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/92.3.205", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032301848"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0960-0760(94)90131-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032610493"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0002-9149(93)90035-b", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033906574"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6601879", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037763577", 
          "https://doi.org/10.1038/sj.bjc.6601879"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6601879", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037763577", 
          "https://doi.org/10.1038/sj.bjc.6601879"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00000421-198212000-00014", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045278392"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00000421-198212000-00014", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045278392"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/jm950749y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1055957296"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/jm950749y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1055957296"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2012-08", 
    "datePublishedReg": "2012-08-01", 
    "description": "PURPOSE: Abiraterone is the active metabolite of the pro-drug abiraterone acetate (AA) and a selective inhibitor of CYP17, a key enzyme in testosterone synthesis, and improves overall survival in postdocetaxel metastatic castration-resistant prostate cancer (mCRPC). This open-label, single-arm phase 1b study was conducted to assess the effect of AA and abiraterone on the QT interval.\nMETHODS: The study was conducted in 33 patients with mCRPC. Patients received AA 1,000\u00a0mg orally once daily\u00a0+\u00a0prednisone 5\u00a0mg orally twice daily. Electrocardiograms (ECGs) were collected in triplicate using 12-lead Holter monitoring. Baseline ECGs were obtained on Cycle 1 Day-1. Serial ECG recordings and time-matched pharmacokinetic (PK) blood samples were collected over 24\u00a0h on Cycle 1 Day 1 and Cycle 2 Day 1. Serial PK blood samples were also collected over 24\u00a0h on Cycle 1 Day 8.\nRESULTS: After AA administration, the upper bound of the 2-sided 90\u00a0% confidence interval (CI) for the mean baseline-adjusted QTcF change was <10\u00a0ms; no patients discontinued due to QTc prolongation or adverse events. No apparent relationship between change in QTcF and abiraterone plasma concentrations was observed [estimated slope (90\u00a0% CI): 0.0031 (-0.0040, 0.0102)].\nCONCLUSIONS: There is no significant effect of AA plus prednisone on the QT/QTc interval in patients with mCRPC.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00280-012-1916-9", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1088364", 
        "issn": [
          "0344-5704", 
          "1432-0843"
        ], 
        "name": "Cancer Chemotherapy and Pharmacology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "70"
      }
    ], 
    "name": "Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer", 
    "pagination": "305-313", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "ff8225b8d9e92a3b4088e8820c6f3a3432f6c8b1d1d197414b8747908616759e"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "22752297"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7806519"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00280-012-1916-9"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1053642864"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00280-012-1916-9", 
      "https://app.dimensions.ai/details/publication/pub.1053642864"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T17:33", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8672_00000516.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs00280-012-1916-9"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00280-012-1916-9'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00280-012-1916-9'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00280-012-1916-9'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00280-012-1916-9'


 

This table displays all metadata directly associated to this object as RDF triples.

259 TRIPLES      21 PREDICATES      57 URIs      36 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00280-012-1916-9 schema:about N140a9aa3a5aa4860872018e1f8afd8b5
2 N1b2fe92cdb5f4bfba191019e1699e0ec
3 N2aaad3dfbbc64ef6a2d8df7d132102cd
4 N44bed5e340164c8391beae05e7eb721b
5 N505973d6a59943ac804a9a6cd6a372fe
6 N524a68a63a21492daf83ee06011a69f8
7 N5916dc813b5a4ab59327b01dd3eedea2
8 N6df7f58a92fe436c85075ede8c030770
9 N88ab7845cf7340e0aa7dcef2e30ef3cf
10 N985d7f9bd26a4a7dadf93e92eadd8324
11 Nb4e75a5f84664caeb55e4a1aa85bf59f
12 Nd5877fbada5346bcada5139e5a9ac4fe
13 Ne81f5f4af14a4fd49321f42242b94fa1
14 Nec8abc82801c41e79808d559f4ce4722
15 Nf8a46a6b27044a88929340e73538a863
16 anzsrc-for:11
17 anzsrc-for:1112
18 schema:author N033f92d3dc1b482fa656a63b159bc289
19 schema:citation sg:pub.10.1038/sj.bjc.6601879
20 https://doi.org/10.1016/0002-9149(93)90035-b
21 https://doi.org/10.1016/0960-0760(94)90131-7
22 https://doi.org/10.1016/j.coph.2008.06.004
23 https://doi.org/10.1021/jm950749y
24 https://doi.org/10.1046/j.1365-2125.2002.01627.x
25 https://doi.org/10.1056/nejmoa1014618
26 https://doi.org/10.1093/annonc/mdq369
27 https://doi.org/10.1093/jnci/92.3.205
28 https://doi.org/10.1097/00000421-198212000-00014
29 https://doi.org/10.1200/jco.2007.12.4487
30 https://doi.org/10.1200/jco.2007.15.9749
31 https://doi.org/10.1200/jco.2009.25.9259
32 schema:datePublished 2012-08
33 schema:datePublishedReg 2012-08-01
34 schema:description PURPOSE: Abiraterone is the active metabolite of the pro-drug abiraterone acetate (AA) and a selective inhibitor of CYP17, a key enzyme in testosterone synthesis, and improves overall survival in postdocetaxel metastatic castration-resistant prostate cancer (mCRPC). This open-label, single-arm phase 1b study was conducted to assess the effect of AA and abiraterone on the QT interval. METHODS: The study was conducted in 33 patients with mCRPC. Patients received AA 1,000 mg orally once daily + prednisone 5 mg orally twice daily. Electrocardiograms (ECGs) were collected in triplicate using 12-lead Holter monitoring. Baseline ECGs were obtained on Cycle 1 Day-1. Serial ECG recordings and time-matched pharmacokinetic (PK) blood samples were collected over 24 h on Cycle 1 Day 1 and Cycle 2 Day 1. Serial PK blood samples were also collected over 24 h on Cycle 1 Day 8. RESULTS: After AA administration, the upper bound of the 2-sided 90 % confidence interval (CI) for the mean baseline-adjusted QTcF change was <10 ms; no patients discontinued due to QTc prolongation or adverse events. No apparent relationship between change in QTcF and abiraterone plasma concentrations was observed [estimated slope (90 % CI): 0.0031 (-0.0040, 0.0102)]. CONCLUSIONS: There is no significant effect of AA plus prednisone on the QT/QTc interval in patients with mCRPC.
35 schema:genre research_article
36 schema:inLanguage en
37 schema:isAccessibleForFree true
38 schema:isPartOf N366159837b5f418fa35390529627deed
39 Ne99a5f034a874fb08b74c0d729e07bb8
40 sg:journal.1088364
41 schema:name Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer
42 schema:pagination 305-313
43 schema:productId N266f6f23ffd8489696b17ebb48cf669b
44 N3fdc36582739402f95d2a68b5e18aa95
45 N8b06256b0cc1416eb4397a1079060c3f
46 Ncd0f86d5d0d7470db41bc99fae88ada7
47 Nd0af14aa3011450c8939320f9596754e
48 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053642864
49 https://doi.org/10.1007/s00280-012-1916-9
50 schema:sdDatePublished 2019-04-10T17:33
51 schema:sdLicense https://scigraph.springernature.com/explorer/license/
52 schema:sdPublisher N37ab30a6990149d7a87c3c3398d286aa
53 schema:url http://link.springer.com/10.1007%2Fs00280-012-1916-9
54 sgo:license sg:explorer/license/
55 sgo:sdDataset articles
56 rdf:type schema:ScholarlyArticle
57 N033f92d3dc1b482fa656a63b159bc289 rdf:first sg:person.013317163017.31
58 rdf:rest Nafd2f5a66b714d20b03450ee35f770fe
59 N140a9aa3a5aa4860872018e1f8afd8b5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
60 schema:name Androstadienes
61 rdf:type schema:DefinedTerm
62 N16c2284d00454bb0893fc244d41e60ff schema:name British Columbia Cancer Agency, Vancouver, BC, USA
63 rdf:type schema:Organization
64 N1b2fe92cdb5f4bfba191019e1699e0ec schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
65 schema:name Androgens
66 rdf:type schema:DefinedTerm
67 N266f6f23ffd8489696b17ebb48cf669b schema:name dimensions_id
68 schema:value pub.1053642864
69 rdf:type schema:PropertyValue
70 N2aaad3dfbbc64ef6a2d8df7d132102cd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
71 schema:name Humans
72 rdf:type schema:DefinedTerm
73 N2ef19133309e40848b76eb9f034c5ba4 rdf:first sg:person.01205422461.29
74 rdf:rest N5ae81a9c3d8f41bdba2972e80de3f7b0
75 N366159837b5f418fa35390529627deed schema:volumeNumber 70
76 rdf:type schema:PublicationVolume
77 N3736cdff9c1a428982f7e907f07706ff rdf:first sg:person.01065235371.09
78 rdf:rest Ncaa90c8bb7794f04928b2f523837cfeb
79 N37ab30a6990149d7a87c3c3398d286aa schema:name Springer Nature - SN SciGraph project
80 rdf:type schema:Organization
81 N3fdc36582739402f95d2a68b5e18aa95 schema:name doi
82 schema:value 10.1007/s00280-012-1916-9
83 rdf:type schema:PropertyValue
84 N44bed5e340164c8391beae05e7eb721b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
85 schema:name Orchiectomy
86 rdf:type schema:DefinedTerm
87 N452fed293900407f85d33c33481d798b rdf:first sg:person.01253457116.57
88 rdf:rest N92bf54467556404ea9e788624c3caf8e
89 N505973d6a59943ac804a9a6cd6a372fe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Steroid 17-alpha-Hydroxylase
91 rdf:type schema:DefinedTerm
92 N524a68a63a21492daf83ee06011a69f8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
93 schema:name Prostatic Neoplasms
94 rdf:type schema:DefinedTerm
95 N5916dc813b5a4ab59327b01dd3eedea2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
96 schema:name Drug Administration Schedule
97 rdf:type schema:DefinedTerm
98 N5ae81a9c3d8f41bdba2972e80de3f7b0 rdf:first sg:person.01253535661.37
99 rdf:rest rdf:nil
100 N697049346435491baa2aa10f0d70910d rdf:first sg:person.01137307261.17
101 rdf:rest N2ef19133309e40848b76eb9f034c5ba4
102 N6df7f58a92fe436c85075ede8c030770 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Electrocardiography
104 rdf:type schema:DefinedTerm
105 N88ab7845cf7340e0aa7dcef2e30ef3cf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Heart Rate
107 rdf:type schema:DefinedTerm
108 N8b06256b0cc1416eb4397a1079060c3f schema:name pubmed_id
109 schema:value 22752297
110 rdf:type schema:PropertyValue
111 N92bf54467556404ea9e788624c3caf8e rdf:first sg:person.01142277551.95
112 rdf:rest Ne4554497dc3f46b08c6ac48f697a659f
113 N937030232d6d4bb08e0e58e1ef61c553 rdf:first sg:person.012576447577.98
114 rdf:rest N452fed293900407f85d33c33481d798b
115 N985d7f9bd26a4a7dadf93e92eadd8324 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Long QT Syndrome
117 rdf:type schema:DefinedTerm
118 N9ef006f29d5c4e53a861deb2f52aa84b rdf:first sg:person.01071174061.78
119 rdf:rest N697049346435491baa2aa10f0d70910d
120 Nafd2f5a66b714d20b03450ee35f770fe rdf:first sg:person.01142252161.65
121 rdf:rest N3736cdff9c1a428982f7e907f07706ff
122 Nb4e75a5f84664caeb55e4a1aa85bf59f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Abiraterone Acetate
124 rdf:type schema:DefinedTerm
125 Nc2b02bf08d3c4401afc39380fa111a34 schema:name British Columbia Cancer Agency, Vancouver, BC, USA
126 rdf:type schema:Organization
127 Ncaa90c8bb7794f04928b2f523837cfeb rdf:first sg:person.01316567341.55
128 rdf:rest N937030232d6d4bb08e0e58e1ef61c553
129 Ncd0f86d5d0d7470db41bc99fae88ada7 schema:name readcube_id
130 schema:value ff8225b8d9e92a3b4088e8820c6f3a3432f6c8b1d1d197414b8747908616759e
131 rdf:type schema:PropertyValue
132 Nd0af14aa3011450c8939320f9596754e schema:name nlm_unique_id
133 schema:value 7806519
134 rdf:type schema:PropertyValue
135 Nd5877fbada5346bcada5139e5a9ac4fe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Antineoplastic Combined Chemotherapy Protocols
137 rdf:type schema:DefinedTerm
138 Ne4554497dc3f46b08c6ac48f697a659f rdf:first sg:person.01023060661.71
139 rdf:rest N9ef006f29d5c4e53a861deb2f52aa84b
140 Ne81f5f4af14a4fd49321f42242b94fa1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Neoplasms, Hormone-Dependent
142 rdf:type schema:DefinedTerm
143 Ne99a5f034a874fb08b74c0d729e07bb8 schema:issueNumber 2
144 rdf:type schema:PublicationIssue
145 Nec8abc82801c41e79808d559f4ce4722 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Prednisone
147 rdf:type schema:DefinedTerm
148 Nf8a46a6b27044a88929340e73538a863 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Male
150 rdf:type schema:DefinedTerm
151 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
152 schema:name Medical and Health Sciences
153 rdf:type schema:DefinedTerm
154 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
155 schema:name Oncology and Carcinogenesis
156 rdf:type schema:DefinedTerm
157 sg:journal.1088364 schema:issn 0344-5704
158 1432-0843
159 schema:name Cancer Chemotherapy and Pharmacology
160 rdf:type schema:Periodical
161 sg:person.01023060661.71 schema:affiliation https://www.grid.ac/institutes/grid.497530.c
162 schema:familyName Jiao
163 schema:givenName J. J.
164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01023060661.71
165 rdf:type schema:Person
166 sg:person.01065235371.09 schema:affiliation https://www.grid.ac/institutes/grid.476933.c
167 schema:familyName Shore
168 schema:givenName N. D.
169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01065235371.09
170 rdf:type schema:Person
171 sg:person.01071174061.78 schema:affiliation https://www.grid.ac/institutes/grid.497530.c
172 schema:familyName Gonzalez
173 schema:givenName M.
174 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01071174061.78
175 rdf:type schema:Person
176 sg:person.01137307261.17 schema:affiliation https://www.grid.ac/institutes/grid.497530.c
177 schema:familyName Trinh
178 schema:givenName A.
179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01137307261.17
180 rdf:type schema:Person
181 sg:person.01142252161.65 schema:affiliation Nc2b02bf08d3c4401afc39380fa111a34
182 schema:familyName Chi
183 schema:givenName K. N.
184 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01142252161.65
185 rdf:type schema:Person
186 sg:person.01142277551.95 schema:affiliation https://www.grid.ac/institutes/grid.497530.c
187 schema:familyName Kheoh
188 schema:givenName T.
189 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01142277551.95
190 rdf:type schema:Person
191 sg:person.01205422461.29 schema:affiliation N16c2284d00454bb0893fc244d41e60ff
192 schema:familyName Pankras
193 schema:givenName C.
194 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01205422461.29
195 rdf:type schema:Person
196 sg:person.01253457116.57 schema:affiliation https://www.grid.ac/institutes/grid.497530.c
197 schema:familyName Acharya
198 schema:givenName M.
199 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01253457116.57
200 rdf:type schema:Person
201 sg:person.01253535661.37 schema:affiliation https://www.grid.ac/institutes/grid.497530.c
202 schema:familyName Tran
203 schema:givenName N.
204 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01253535661.37
205 rdf:type schema:Person
206 sg:person.012576447577.98 schema:affiliation https://www.grid.ac/institutes/grid.497530.c
207 schema:familyName Molina
208 schema:givenName A.
209 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012576447577.98
210 rdf:type schema:Person
211 sg:person.01316567341.55 schema:affiliation https://www.grid.ac/institutes/grid.240614.5
212 schema:familyName Pili
213 schema:givenName R.
214 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01316567341.55
215 rdf:type schema:Person
216 sg:person.013317163017.31 schema:affiliation https://www.grid.ac/institutes/grid.477989.c
217 schema:familyName Tolcher
218 schema:givenName A. W.
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013317163017.31
220 rdf:type schema:Person
221 sg:pub.10.1038/sj.bjc.6601879 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037763577
222 https://doi.org/10.1038/sj.bjc.6601879
223 rdf:type schema:CreativeWork
224 https://doi.org/10.1016/0002-9149(93)90035-b schema:sameAs https://app.dimensions.ai/details/publication/pub.1033906574
225 rdf:type schema:CreativeWork
226 https://doi.org/10.1016/0960-0760(94)90131-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032610493
227 rdf:type schema:CreativeWork
228 https://doi.org/10.1016/j.coph.2008.06.004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030776578
229 rdf:type schema:CreativeWork
230 https://doi.org/10.1021/jm950749y schema:sameAs https://app.dimensions.ai/details/publication/pub.1055957296
231 rdf:type schema:CreativeWork
232 https://doi.org/10.1046/j.1365-2125.2002.01627.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1027770955
233 rdf:type schema:CreativeWork
234 https://doi.org/10.1056/nejmoa1014618 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018044872
235 rdf:type schema:CreativeWork
236 https://doi.org/10.1093/annonc/mdq369 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007763175
237 rdf:type schema:CreativeWork
238 https://doi.org/10.1093/jnci/92.3.205 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032301848
239 rdf:type schema:CreativeWork
240 https://doi.org/10.1097/00000421-198212000-00014 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045278392
241 rdf:type schema:CreativeWork
242 https://doi.org/10.1200/jco.2007.12.4487 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031178629
243 rdf:type schema:CreativeWork
244 https://doi.org/10.1200/jco.2007.15.9749 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000521921
245 rdf:type schema:CreativeWork
246 https://doi.org/10.1200/jco.2009.25.9259 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026303880
247 rdf:type schema:CreativeWork
248 https://www.grid.ac/institutes/grid.240614.5 schema:alternateName Roswell Park Cancer Institute
249 schema:name Roswell Park Cancer Institute, Buffalo, NY, USA
250 rdf:type schema:Organization
251 https://www.grid.ac/institutes/grid.476933.c schema:alternateName Carolina Urologic Research Center
252 schema:name Carolina Urologic Research Center, Myrtle Beach, SC, USA
253 rdf:type schema:Organization
254 https://www.grid.ac/institutes/grid.477989.c schema:alternateName South Texas Accelerated Research Therapeutics
255 schema:name South Texas Accelerated Research Therapeutics (START), Center for Cancer Care, 4383 Medical Drive, 78229, San Antonio, TX, USA
256 rdf:type schema:Organization
257 https://www.grid.ac/institutes/grid.497530.c schema:alternateName Janssen (United States)
258 schema:name Janssen Research & Development LLC, Raritan, NJ, USA
259 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...